ArticleSleep medicine: X2026
Effects of PeptiSleep™ on sleep modification and biometrics in adults with sleep impairment: A randomised, placebo-controlled pilot study.
Article in Sleep medicine: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sleep is vital for longevity and daily function but is under threat due to modern culture. While pharmaceuticals induce and prolong sleep, dependency and side effects can be significant. Artificial intelligence and peptide science have accelerated the accurate identification of natural, bioavailable compounds in a way previously limited to pharmaceutical discovery. This randomised, placebo-controlled, parallel pilot study investigated the effects of a rice protein hydrolysate, PeptiSleep™, on sleep quality in 26 adults (18-65 years old) with sleep impairment over 56 days. This small, single-blinded study was designed as exploratory; findings should be interpreted accordingly, with no adjustments made for multiple comparisons on secondary endpoints. PeptiSleep™ group scores were higher than the placebo in all sub-categories of the Leeds Sleep Evaluation Questionnaire, with nominally significant changes in Getting To Sleep (p = 0.050) and Quality Of Sleep (p = 0.036) domains. The Profile of Mood States indicated a nominally significant difference (p = 0.050) in total mood disturbance alongside non-significant differences in sleep diaries and questionnaires related to stress, anxiety, sleepiness, and insomnia. Exploratory analysis of objective biometrics, tracked passively using Oura wearable technology suggested potential differences in heart rate variability, sleep architecture, and latency between groups. PeptiSleep™ is the first
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.